This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Müller, J. Articles by Hetzer, R. Search for Related Content PubMed PubMed Citation Articles by Müller, J. Articles by Hetzer, R.

(Circulation. 1997;96:542-549.)
© 1997 American Heart Association, Inc.

Articles

Weaning From Mechanical Cardiac Support in Patients With Idiopathic Dilated Cardiomyopathy

Johannes Müller, MD; Gerd Wallukat, PhD; Yu-Guo Weng, MD; Michael Dandel, MD; Susanne Spiegelsberger, MD; Sabine Semrau, MD; Kersten Brandes, MD; Vassilis Theodoridis, MD; Matthias Loebe, MD; Rudolf Meyer, MD; ; Roland Hetzer, MD

From the German Heart Institute Berlin, Department of Cardiac and Vascular Surgery, and the Max-Delbrück-Center, Berlin, Germany (G.W.).

Correspondence to Johannes Müller, MD, German Heart Institute Berlin, Augustenburger Platz #1, 13353 Berlin, Germany.

Background Implantation of mechanical cardiac support systems (MCSS) in patients with idiopathic dilated cardiomyopathy (IDC) may improve cardiac function and allow explantation of the device. We report of long-term effects of ventricular unloading on cardiac function, humoral anti-ß1-adrenoceptor autoantibodies (A-ß₁-AABs), and myocardial fibrosis.

Methods and Results Seventeen patients in New York Heart Association functional class IV with nonischemic IDC received MCSS. All had a cardiac index of <1.6 L · min^-1 · m^-2 of body surface area, a left ventricular ejection fraction (LVEF) of <16%, and a left ventricular internal diameter in diastole (LVIDd) of >68 mm and tested positive for A-ß₁-AABs. Echocardiographic evaluation, serum tests for A-ß₁-AABs, and histological assessment of myocardial fibrosis were performed before and after MCSS implantation. The mean support duration was 230±201 days. Six patients died, four were transplanted, and two are still on MCSS. Five patients with significant cardiac recovery (mean LVIDd, 54±2.3 mm; LVEF, 47±3.7%) were weaned after 160 to 794 days and are now device free for 51 to 592 days. A-ß₁-AABs disappeared gradually during MCSS without increase after weaning; cardiac function and volume density of fibrosis remained normal. Nine patients' cardiac function hardly improved during ventricular unloading.

Conclusions Cardiac function can be normalized in selected patients with end-stage IDC by MCSS. The degree of preoperative myocardial fibrosis may be an indicator for outcome; A-ß₁-AABs can be used to monitor myocyte recovery. Weaning from MCSS offers an alternative to cardiac transplantation in certain patients.

Key Words: cardiomyopathy • assist devices • implantation